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Abstract
The red blood cell distribution width (RDW) is a simple, 
rapid, inexpensive and straightforward hematological 
parameter, reflecting the degree of anisocytosis 
in vivo . The currently available scientific evidence 
suggests that RDW assessment not only predicts the 
risk of adverse outcomes (cardiovascular and all-cause 
mortality, hospitalization for acute decompensation 
or worsened left ventricular function) in patients with 
acute and chronic heart failure (HF), but is also a 
significant and independent predictor of developing 
HF in patients free of this condition. Regarding the 
biological interplay between impaired hematopoiesis and 
cardiac dysfunction, many of the different conditions 
associated with increased heterogeneity of erythrocyte 
volume (i.e. , ageing, inflammation, oxidative stress, 
nutritional deficiencies and impaired renal function), 
may be concomitantly present in patients with HF, 
whilst anisocytosis may also directly contribute to the 
development and worsening of HF. In conclusion, the 
longitudinal assessment of RDW changes over time may 
be considered an efficient measure to help predicting 
the risk of both development and progression of HF.
Key words: Heart failure; Heart disease; Mortality; 
Erythrocytes; Red blood cell distribution width
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evidence suggests that longitudinal assessment of red 
blood cell distribution width over time may be considered 
an efficient measure to help predicting the risk of both 
development and progression of heart failure.
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INTRODUCTION 
Heart failure definition, etiology and epidemiology
As a complex clinical syndrome, heart failure (HF) is 
characterized by certain symptoms and signs such as 
dyspnea and fatigue, which impair exercise tolerance, 
fluid retention, and may provoke pulmonary and/or 
splanchnic congestion, ankle swelling, peripheral 
edema, elevated jugular venous pressure, and 
pulmonary crackles[1,2]. These are principally due to 
structural and/or functional cardiac abnormalities, which 
result in an impaired cardiac output and/or elevated 
intracardiac pressures[1]. The classification of the 
different types of HF is based on left ventricle ejection 
fraction (LVEF) as follows: (1) HF with preserved LVEF 
(HFpEF), i.e., patients with normal LVEF (≥ 50%); (2) 
HF with reduced EF (HFrEF), i.e., patients with reduced 
LVEF (< 40%); (3) HF with midrange EF (HFmrEF), i.e., 
patients with an LVEF in the range of 40%-49%[1].
The etiology of HF is varied, including a wide range of 
pathologies both cardiovascular and non-cardiovascular. 
Many patients will suffer different diseases at the same 
time, which ultimately trigger the HF. Nonetheless, a 
history of ischemic heart disease (IHD) and myocardial 
infarction or revascularization is very common among 
patients with HF[1]. Thus, among the most important 
causes of death in patients with HF are cardiovascular 
diseases, mainly sudden death and worsening HF[3,4]. It 
seems that HFpEF and HFrEF have different etiological 
profiles, since patients with HFpEF are more often 
older, women and have a history of hypertension and 
atrial fibrillation (AF). However, a history of myocardial 
infarction is uncommonly found in HFpEF patients[5].
The prevalence of HF in developed countries is 
considered to be around 1%-2% of the adult general 
population[1]. The incidence increases with age, up to ≥ 
10% among people > 70 years of age[6]. For instance, 
20% of American population ≥ 40 years of age will 
develop HF[7] and nearly 5.1 million people in the United 
States already have clinical signs and symptoms of 
HF, with a prevalence that seems to be constantly 
increasing[8], so that approximately 33% of men and 28% 
of women ≥ 55 years will develop HF worldwide[9]. Using 
the conventional definition, the percentage of patients 
with HFpEF ranges from 22% to 73%[1]. Likewise, the 
incidence of HF may be decreasing, more for HFrEF than 
for HFpEF[10,11]. Inequalities in the epidemiology of HF 
have been also reported. A high risk of developing HF has 
been reported in black populations[12], whilst the incidence 
seems the lowest among white women[13] and the highest 
among black men[14], with a higher 5-year mortality[15]. 
Non-Hispanic black males have a higher prevalence (4.5%) 
than females (3.8%), whilst non-Hispanic white males also 
have a higher prevalence (2.7%) than females (1.8%)[8].
Many prognostic biomarkers of death and/or 
hospitalization in patients with HF have been studied and 
identified[1]. Unfortunately, their clinical uses remains 
limited due to the challenges in stratifying the risk of HF 
patients. Furthermore, multiple prognostic risk scores 
have been developed in HF[4,16,17], and may be helpful to 
predict death in these patients. However, they are less 
useful to predict HF hospitalizations[16,17]. In fact, several 
studies only reported a moderate accuracy of these 
models to predict mortality, whilst they were basically 
less accurate for predicting hospitalization[16,17].
ANISOCYTOSIS
The erythrocytes, also known as red blood cells (RBCs), 
are non-nuclear corpuscular elements of blood produced 
in the bone from erythroid colony-forming unit-erythroid 
(CFU-E) progenitors, which undergo a complex 
process of maturation (also known as erythropoiesis) 
into proerythroblasts, erythroblasts, reticulocytes 
and, finally, into mature erythrocytes[18]. The ensuing 
conversion of erythroblasts into reticulocytes and 
erythrocytes is accompanied by the loss of the nucleus, 
which makes erythrocytes virtually terminal elements 
(Figure 1). 
The entire process of erythropoiesis is regulated 
by several transcription factors, chromatin modifiers, 
cytokines, and hormones, the most important of which 
is erythropoietin (Epo), which not only stimulates 
the proliferation and differentiation of hematopoietic 
precursors but is also essential for survival of newly 
generated RBCs[18]. Physiological erythropoiesis mainly 
occurs in the bone marrow, so that proerythroblasts and 
erythroblasts (in their different stages of maturation, i.e., 
basophilic, polychromatophilic and orthochromatic) are 
normally absent in the bloodstream, whilst the number 
of reticulocytes is typically < 1% of the total RBC 
population[19]. The leading function of RBCs is carrying 
oxygen throughout the bloodstream, from the lungs 
to the peripheral tissues, mainly bound to hemoglobin, 
the most important protein contained within the 
erythrocytes. The total number of mature RBCs in 
adult human blood is usually comprised between 4.7 × 
1012/L-6.1 × 1012/L in men and 4.2 × 1012/L-5.4 × 1012/L 
in women, respectively, with a mean survival time in 
blood of approximately 100-120 d. A reduction of RBC 
number below these conventional thresholds is known 
as “anemia”, which is usually diagnosed when the level 
of hemoglobin in blood falls below 130 g/L in men and 
120 g/L in women, respectively[18].
A typical mature erythrocyte appears as a disc-shaped 
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element with a pale-staining central area, a diameter 
comprised between 6-8 μm and a total volume (also 
known as mean corpuscular volume (MCV)] comprised 
between 80-100 fL. RBC with abnormal volumes, 
either reduced or increased, are conventionally called 
microcytic or macrocytic, respectively[19]. RBCs display 
a physiological size heterogeneity in adult human blood, 
which is usually measured in terms of RBC distribution 
width (RDW). This simple and straightforward parameter 
can thus be expressed both in absolute value, as the 
standard deviation (SD) of erythrocyte volumes (RDW-
SD), or as the coefficient of variation (RDW-CV) of 
erythrocyte volumes [i.e., (RDW-SD)/ (MCV)*100]. The 
normal range of RDW-CV is 11.5-14.5% but often varies 
according to the technique used for its assessment 
by the different commercially available hematological 
analyzers[20]. Although a decreased RDW value is very 
8 February 26, 2018|Volume 10|Issue 2|WJC|www.wjgnet.com
uncommon and has no clinically significance[21], an 
increase of this parameter is called anisocytosis and 
has many important consequences on the future risk of 
adverse cardiovascular events and mortality in the general 
population[22], as well as in patients with HF or in those 
at risk of developing HF[23], as more comprehensively 
discussed in the next sections of this article. 
Anisocytosis can hence be essentially defined 
as a DW value exceeding the analyzer-dependent 
threshold[24]. More practically, it can be defined as the 
presence of erythrocytes with a large size heterogeneity 
in peripheral venous blood, as simplified in Figure 2. 
The partial or complete derangement of many biological 
pathways, mainly including aging, inflammation, 
oxidative stress, nutritional deficiencies, and impaired 
renal function, has been straightforwardly associated with 
disrupted erythropoiesis resulting in variable degrees of 
Bone marrow
Erythroblast 
(basophilic)
Erythroblast 
(polychromatophilic)
Blood
ErythrocyteReticulocyte
Erythroblast 
(orthochromatic)
Proerythroblast
Figure 1  Physiological erythropoiesis.
Figure 2  Pathophysiological mechanisms causing anisocytosis. RDW: Red blood cell distribution width.
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and laboratory parameters, each 1% increase in RDW 
value was associated with 14% increased all-cause 
mortality (HR = 1.14; 95%CI: 1.05-1.24). Importantly, 
each 1% increase in RDW value was also associated 
with 15% higher risk (HR = 1.15; 95%CI: 1.05-1.26) 
of developing symptomatic HF on follow-up.
These earlier findings were then replicated in a 
vast number of prospective, retrospective and cross-
sectional studies, which were meta-analyzed by Huang 
et al[28], Shao et al[29] and, more recently, by Hou et al[30] 
(Table 2).
More specifically, in the meta-analysis by Huang and 
collaborators[28], each 1% increase in RDW value was 
associated with 10% enhanced risk of future mortality 
events (HR = 1.10; 95%CI: 1.07-1.13) in patients with 
HF. No substantial difference was observed between 
retrospective (n = 4; HR, 1.09 and 95%CI: 1.02-1.17) 
and prospective (n = 5; HR = 1.10 and 95%CI: 
1.05-1.15) studies, whilst a greater risk was observed in 
studies with follow-up >2 years (n = 5; HR = 1.13 and 
95%CI: 1.09-1.16) than in those with shorter follow-up 
(n = 4; HR = 1.04; 95%CI: 1.02-1.06). In the ensuing 
meta-analysis of Shao et al[29], each 1% increase in 
RDW value was associated with 19% enhanced risk 
of major adverse cardiovascular events (HR = 1.19; 
95%CI: 1.08-1.30), with 12% higher risk of death (HR 
= 1.12; 95%CI: 1.08-1.16), as well as with 9% higher 
risk of hospitalization (HR = 1.09, 95%CI: 1.03-1.16) in 
patients with HF. Notably, the association between RDW 
value and death was found slightly stronger in patients 
with chronic HF (HR = 1.13, 95%CI: 1.08-1.18) than in 
those with acute HF (HR = 1.09; 95%CI: 1.04-1.15). 
More recently, the meta-analysis of Hou et al[30] showed 
that each 1% increase in RDW value was associated 
with 11% higher risk of death (HR = 1.11; 95%CI: 
1.04-1.14) in patients with HF, whilst each 1% increase 
in RDW value was associated with 11% higher risk of 
HF in patients with preexisting cardiovascular disease 
(HR = 1.11; 95%CI: 1.05-1.17). 
Dynamic changes of anisocytosis in heart failure patients
Although the notion that baseline RDW assessment may 
help to predict both unfavorable outcomes in patients 
with acute or chronic HF as well as the risk of developing 
HF in patients without this condition seems now quite 
straightforward (Table 2), an alternative concept is 
strongly emerging, indicating that serial assessment of 
RDW over time may be more clinically meaningful and 
informative than the admission value (Table 3). 
The first study which assessed the significance 
of longitudinal RDW changes in patients with HF was 
published by Cauthen et al[31]. The authors retrospectively 
analyzed data from 6159 ambulatory chronic HF patients, 
with the aim of exploring the potential association 
between clinical outcomes and RDW changes over a 
1-year follow-up period. Although each 1% increase in 
baseline RDW value was independently associated with 
9% enhanced risk of 1-year all-cause mortality [relative 
risk (RR) = 1.09; 95%CI: 1.01-1.17], this association 
anisocytosis (Table 1)[25]. Therefore, the aim of this article 
is to provide an overview of the epidemiological and 
biological evidence linking anisocytosis and HF.
ANISOCYTOSIS AND HEART FAILURE 
Baseline assessment of anisocytosis in HF patients
The very first large prospective study which explored 
the clinical significance of measuring RDW in patients 
with HF was published in 2007 by Felker et al[26]. Briefly, 
the authors measured RDW values at enrollment in 
2679 chronic HF patients recruited from the North 
American Candesartan in HF: Assessment of Reduction 
in Mortality and Morbidity (CHARM) study (validation 
cohort), who were followed-up for at least 2 years for 
collecting data on death or hospitalization for managing 
worsened HF. The data obtained in this cohort were 
then validated in a replication dataset consisting of 
additional 2140 HF patients enrolled from the Duke 
Databank in 1969, and with follow-up data completely 
available for more than 96% patients. In the final 
multivariable analysis, including all significant clinical 
and laboratory parameters, each 1 SD increase of 
RDW in the CHARM Cohort was associated with 17% 
higher risk of cardiovascular death or hospitalization for 
HF [hazard ratio (HR), 1.17; 95% confidence interval 
(95%CI), 1.10-1.25] and 12% higher risk (HR = 
1.12; 95%CI: 1.03-1.20) of all-cause mortality. In the 
validation cohort, each 1 SD increase of RDW was also 
associated as with 29% enhanced risk (HR = 1.29; 
95%CI: 1.16-1.43) of all-cause mortality.
The following year, Tonelli et al[27] published the 
results of another large prospective study, based on 
4111 participants of the Cholesterol and Recurrent 
Events study, free of HF at baseline, who had their RDW 
value measured at enrollment and were then followed-
up for a median period of approximately 60 mo. In a 
multivariable model adjusted for all significant clinical 
Table 1  Differential diagnosis of anemia based on mean 
corpuscular volume and red blood cell distribution width
Conditions MCV RDW
Chronic diseases anemia ↓ N
Heterozygous thalassemia ↓ N
Iron deficiency ↓ ↑
β-thalassemia ↓ ↑
Sickle cell trait ↓ N
Haemolytic anemia N/↓ ↑
Hereditary spherocytosis N/↓ ↑
Sickle cell disease N ↑
Haemorrhage N N
Blood transfusions N ↑
Chronic liver disease N/↑ ↑
Aplastic anemia ↑ N
Folate deficiency ↑ ↑
Vitamin B12 deficiency ↑ ↑
Myelodysplastic syndrome ↑ ↑
MCV: Mean corpuscular volume; RDW: Red blood cell distribution width; 
N: Normal; ↓: Decreased; ↑: Increased.
Lippi G et al . Red blood cell distribution width in heart failure
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Table 2  Meta-analyses exploring the association between baseline red blood cell distribution width value and heart failure
Ref.               Variable                Outcome measure        Baseline RDW
Huang et al[28], 2014 1% increase in RDW value Risk of future death in patients with HF HR, 1.10 (95%CI: 1.0-1.13)
Risk of hospitalization in patients with HF HR, 1.09 (95%CI: 1.03-1.16)
Shao et al[29], 2015 1% increase in RDW value Risk of future MACE in patients with HF HR, 1.19 (95%CI: 1.08-1.30)
Risk of future death in patients with HF HR, 1.12 (95%CI: 1.08-1.16)
Hou et al[30], 201 1% increase in RDW value General risk of HF HR, 1.11 (95%CI: 1.05-1.1)
HR, 1.11 (95%CI: 1.04-1.14)
HF: Heart failure; HR: Hazard ratio; MACE: Major adverse cardiovascular events; RDW: Red blood cell distribution width.
Table 3  Studies exploring the association between serial red blood cell distribution width changes and heart failure
Ref. Study design Outcome measure Variable Baseline RDW Longitudinal RDW 
change
Cauthen et al[31], 2012 Retrospective, 6159 patients 
with chronic HF
1-year all-cause 
mortality
1% increase in RDW at 
diagnosis or during 1 year of 
follow-up
RR, 1.09 (95%CI: 
1.01-1.1)
RR, 1.21 (95%CI: 
1.08-1.34)
Makhoul et al[32], 2013 Prospective, 614 patients with 
acute decompensated HF 
followed-up during hospital 
stay
All-cause 
mortality during 
hospital stay
1% increase in RDW value at 
admission or during hospital 
stay
HR, 1.15 (95%CI: 
1.08-1.21)
HR, 1.23 (95%CI: 
1.09-1.38)
Núñez et al[33], 2014 Prospective, 102 patients with 
HF followed-up for 18 mo
All-cause 
mortality during 
follow-up
RDW ≥ 15% at admission or 
during follow-up
Anemic patients: 
HR, 1.04 (95%CI: 
1.00-1.0)
Non-anemic 
patients: HR, 1.11 
(95%CI: 1.05-1.19)
Anemic patients: 
HR, 1.08 (95%CI: 
1.04-1.13)
Non-anemic 
patients: HR, 1.31 
(95%CI: 1.22-1.42) 
Ferreira et al[35], 2016 Retrospective, 502 patients with 
acute decompensated HF
Hospitalization 
for acute 
decompensated 
HF or 180-d 
cardiovascular 
death
RDW ≥ 15% at admission and 
delta RDW > 0 at discharge
OR, 1.29 (95%CI: 
0.1-2.33)
OR, 2.4 (95%CI: 
1.35-4.51)
Muhlestein et al[34], 2016 Prospective, 6414 patients with 
HF followed-up during hospital 
stay
30-d all-cause 
mortality
1% increase in RDW value at 
admission and during hospital 
stay
HR, 1.09 (95%CI: 
1.0-1.12)
HR, 1.09 (95%CI: 
1.03-1.16)
Uemura et al[36], 2016 Prospective, 229 patients with 
acute decompensated HF 
followed-up followed for 692 d
All-cause 
mortality during 
follow-up
RDW ≥ 14.5% at admission 
and positive change of RDW at 
discharge
HR, 1.08 (95%CI: 
0.99-1.19)
HR, 1.19 (95%CI: 
1.01-1.41)
Turcato et al[3], 201 Retrospective, 588 patients with 
acute decompensated HF
30-d all caused 
mortality
ΔRDW > 0.4% at 48 and 96 h - OR, 3.04 (95%CI: 
1.56-5.94) and 3.65 
(95%CI: 2.02-6.15)
HF: Heart failure; HR: Hazard ratio; OR: Odds ratio; RDW: Red blood cell distribution width; RR: Relative risk.
discharged after being diagnosed with acute HF, and 
who had their RDW assessed during a median follow-
up period of 18 mo. The baseline RDW value was found 
to be independently associated with all-cause mortality 
both in anemic (HR = 1.04; 95%CI: 1.00-1.07) and 
non-anemic patients (HR = 1.11; 95%CI: 1.05-1.19), 
but an even stronger association was found between 
the last longitudinally updated RDW (i.e., the mean of 
RDW values measured during follow-up) and death, 
both in anemic (HR = 1.08; 95%CI: 1.04-1.13) and 
non-anemic (1.31; 95%CI: 1.22-1.42) patients.
In an ensuing article, Muhlestein et al[34] published 
the results of a prospective study based on 6414 
patients hospitalized for HF, who had RDW measured 
within 24 h from admission and at least one more time 
during hospitalization. As predictable, each 1% increase 
in RDW measured at baseline was independently 
was found to be much stronger considering longitudinal 
RDW variations (RR for each 1% increase in RDW during 
follow-up, 1.12; 95%CI: 1.08-1.34).
In the study performed in 2013 by Makhoul et al[32], 
the population consisted of a total number of 614 
patients with acute decompensation of HF, who had 
RDW measured at baseline and throughout hospital 
stay, and who were then followed-up for 1 year. 
Interestingly, each 1% increase in RDW value measured 
at baseline was independently associated with a 15% 
higher risk (HR = 1.15; 95%CI: 1.08-1.21) of all-cause 
mortality, but this association was even stronger using 
longitudinal changes of RDW, since each 1% increase 
in RDW value during hospital stay was associated with 
23% higher risk (HR = 1.23; 95%CI: 1.09-1.38) of all-
cause mortality.
In 2014, Núñez et al[33] also studied 1702 patients 
Lippi G et al . Red blood cell distribution width in heart failure
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of RDW showed a significant interaction with diabetes 
(β coefficient, -0.002; P = 0.042), thus highlighting 
that metabolic imbalances may actually have an impact 
on longitudinal changes of RDW. According to these 
findings, anisocytosis may hence be considered not only 
a bystander but also a potential underlying biological 
mechanism explaining the adverse long-term effects of 
diabetes on the risk of hospitalization and mortality in 
patients with HF[39].
THE BIOLOGICAL INTERPLAY BETWEEN 
ANISOCYTOSIS AND HEART FAILURE
Regarding the physiopathological interplay between 
anisocytosis and HF, many of the different conditions 
impairing hematopoiesis, and thus potentially leading to 
a larger size heterogeneity of RBC volumes (Figure 2), 
may be concomitantly present in patients with HF. 
Convincing evidence has accumulated that both cell- 
and cytokine-mediated inflammatory pathways actively 
contribute to development and progression of HF[40]. An 
important interplay has also been recognized between 
inflammation and anisocytosis since inflammation is 
frequently associated with bone marrow dysfunction and 
an increase of circulating premature erythrocytes[41]. 
As regards oxidative stress, an excess production of 
reactive oxygen species (ROS) has been associated 
with both adverse cardiac remodeling[42] and deranged 
hematopoiesis, ultimately leading to anisocytosis[43]. 
Nutritional deficiencies are commonplace in many 
forms of anemia characterized by different degrees of 
anisocytosis[44], but they are also deeply involved in onset 
and progression of HF[45]. The progressive impairment of 
renal function is one of the leading causes of anemia and 
anisocytosis, especially in the elderly[46], but is also an 
important determinant of adverse outcomes in patients 
with HF[47]. Lastly, anisocytosis gradually increases with 
aging as a result of multiple metabolic dysfunctions[48], 
but advanced age is also a strong contributing factor for 
cardiac dysfunction[49]. Therefore, the current evidence 
suggests that anisocytosis and HF may share many 
pathogenetic mechanisms, which may explain why both 
conditions may develop and progress in parallel, thus 
making RDW a reliable marker of cardiac dysfunction. 
Nevertheless, anisocytosis may also play a direct 
role in the onset and progressive worsening of HF. The 
erythrocyte size heterogeneity mirrors a reduced (often 
severely impaired) function of this essential corpuscular 
blood elements. In conditions of high anisocytosis, 
RBCs are often characterized by lower deformability and 
decreased oxygen-carrier capacity, thus contributing 
to reduced oxygenation of many peripheral tissues 
and cells (including cardiomyocytes), whilst abnormal 
erythrocytes may also actively participate in the 
pathogenesis of cardiac fibrosis through promotion or 
amplification of inflammation, cardiomyocyte stress and 
apoptosis[20].
associated with a 9% higher risk of 30-d all-cause 
mortality (HR = 1.09; 95%CI: 1.07-1.12), but a similar 
risk was also observed for each 1% increase in RDW 
during hospitalization (HR = 1.09; 95%CI: 1.03-1.16). 
Interestingly, the risk of 30-d all-cause death was 
considerably magnified (i.e., HR, 2.02) when data of 
both the baseline value and longitudinal changes of 
RDW were combined in the predictive model.
Ferreira et al[35] carried out a retrospective study 
based on 2 independent cohorts of patients admitted to 
the emergency department with acute decompensation 
of HF, the first (i.e., the derivation cohort) consisting 
of 170 patients and the second (i.e., the validation 
cohort) consisting of 332 patients. RDW was measured 
at admission and at hospital discharge, with calculation 
of the ratio between these two values (i.e., ΔRDW). In 
the final model, a RDW value >15% at admission was 
independently associated with a 29% higher risk [odds 
ratio (OR), 1.29; 95%CI: 0.71-2.33] of composite 
outcome (hospitalization for acute decompensated 
HF or 180-d cardiovascular death), whilst such risk 
was found to be substantially higher for patients with 
ΔRDW > 0 (OR = 2.47; 95%CI: 1.35-4.51). Even more 
importantly, the combination of RDW value > 15% at 
admission and ΔRDW > 0 yielded a substantially higher 
risk of composite outcome than the two measures alone 
(OR = 3.40; 95%CI: 1.63-7.08).
Uemura et al[36] studied 229 patients hospitalized for 
acute decompensated HF, who had their RDW measured 
at admission and at hospital discharge, and who were 
then followed-up for a median period of 692 d. Although 
an increased baseline value of RDW at admission (i.e., 
≥ 14.5%) was slightly but non-significantly associated 
with all-cause mortality (HR, 1.08; 95%CI: 0.99-1.19), 
patients exhibiting a positive change (i.e., an increase) 
of RDW between admission and discharge had a 19% 
higher risk of all-cause mortality on follow-up (HR = 
1.19; 95%CI: 1.01-1.41).
More recently, Turcato et al[37] carried out a 
retrospective study including 588 patients hospitalized 
for acute decompensation of HF. RDW values were 
measured at admission and also after 48 h and 96 h of 
hospitalization. Interestingly, a ΔRDW > 0.4% calculated 
between the value at admission and those obtained 
after 48 h and 96 h of hospital stay was independently 
associated with a over 3-fold higher risk of 30-d mortality 
(OR of 48 h ΔRDW, 3.04; 95%CI: 1.56-5.94 and OR of 
96 h ΔRDW, 3.65; 95%CI: 2.02-6.15). 
Finally, Xanthopoulos et al[38] studied 218 patients 
who were admitted to the emergency department 
for acute HF, and who had their RDW measured 
at admission, at discharge and at 4, 8 and 12 mo 
afterward. Follow-up for all-cause mortality or 
rehospitalization was 12 mo. Each 1% increase in RDW 
value at admission was independently associated with 
the composite endpoint both in non-diabetic (HR = 
1.14; 95%CI: 1.01-1.29) and diabetic (1.35; 95%CI: 
1.12-1.62) patients. Notably, the longitudinal changes 
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CONCLUSION
The RDW is a simple, rapid, inexpensive and straightforward 
hematological parameter, which is now automatically 
generated by all commercially available hematological 
analyzers together with the complete blood cells 
count (CBC). Increased RDW values in venous blood 
samples truly mirror the degree of anisocytosis in vivo, 
and can hence be used for diagnostic, prognostic and 
even therapeutic decisions in many acute and chronic 
pathological conditions[50].
The currently available scientific evidence convincingly 
suggests that RDW measurement not only predicts the 
risk of adverse outcomes (cardiovascular and all-cause 
mortality, hospitalization for acute decompensation or 
cardiac dysfunction) in patients with HF but is also a 
significant and independent predictor of developing HF 
in patients free of this condition at the time of baseline 
assessment (Table 2). Nevertheless, the longitudinal 
assessment of RDW changes over time (i.e., during a 
hospital stay or shortly afterward) may be an even more 
effective measure than the baseline value for predicting 
adverse outcomes in patients with chronic, acute 
and even acutely decompensated HF (Table 3). The 
longitudinal assessment of RDW has another important 
advantage, emerging from its insensitivity to the analyzer 
used for its measurement. In fact, longitudinal changes 
either assessed as differences or ratios between the first 
and the following measurements, may help overcoming 
the still unresolved issue of poor harmonization of RDW 
measures[24], which still hampers the identification of 
an universally valid diagnostic or predictive threshold. 
It is also noteworthy in the two studies combining RDW 
values at admission and their subsequent variations 
during follow-up[34,35], the diagnostic efficiency of this 
combination was found to be much better than either 
measure alone for predicting adverse outcomes in HF 
patients.
In conclusion, we suggest that the serial measurement 
of RDW, and especially the combination of admission 
value with subsequent changes during in-hospital or 
home care, may be seen as an affordable and efficient 
tool to help assessing the prognosis of patients with HF 
and for reliably predicting the risk of adverse events.
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